Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Olivier Rixe"'
Autor:
Montaser Shaheen, Jiayi Yu, Charles J. Link, Yousef Zakharia, Ramses F. Sadek, Robert R. McWilliams, Mohammed M. Milhem, Lucinda Tennant, Joseph J. Drabick, Olivier Rixe, Kenneth F. Grossmann, Gabriela R. Rossi, Nicholas N. Vahanian, Erik L. Brincks, Eugene P. Kennedy, Ravindra Kolhe, David H. Munn, Steven S. Shen, Christopher M Smith, Rafal Pacholczyk
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundThe indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity. Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressive
Autor:
Vinay K. Puduvalli, Edouard Dupis, Marc C. Mabray, Audra A. Kerwin, Karen S. SantaCruz, Trisha Wise-Draper, John L. Villano, Olivier Rixe, John C. Morris, Angela N. Johnson, Karen Cline-Parhamovich
BACKGROUND: Ependymomas are rare primary nervous system tumors accounting for about 3% of adult brain tumors in the United States. The current standard of care includes surgical resection and radiation therapy, with more than half experiencing relaps
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83a355eb04e3bbfda6d8cdf9f6d79625
https://europepmc.org/articles/PMC6217694/
https://europepmc.org/articles/PMC6217694/
Autor:
Alain C. Mita, David Martin Darst, Michael A. Postow, Angela Jain, Celia Andreu, Robert Wasserman, Robert Busby, Gerald Steven Falchook, Igor Puzanov, Erika Hamilton, Michael Szarek, Tomislav Dragovich, Narayan Lebaka, Eric K. Rowinsky, Rebecca Redman, Monica M. Mita, Masoud Tavazoie, Shubham Pant, Isabel Kurth, Olivier Rixe, Syed Ahsan Raza, Russell J. Schilder, Kevin B. Kim, R. Donald Harvey, Foster C. Gonsalves, Emerson A. Lim, James Strauss, Bartosz Chmielowski
Publikováno v:
Cancer Research. 80:CT146-CT146
Background: RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene. Binding of ApoE to its receptor LRP8 robustly inhibits angiogenesis and depletes myeloid derived suppressor cells (MDS
Publikováno v:
Expert Opinion on Drug Discovery. 10:925-935
Introduction: Based on extensive preclinical data and abundant evidence for clinical activity, vascular endothelial growth factor receptor (VEGFR) inhibitors are currently standard of care for metastatic renal cell carcinoma (mRCC). Axitinib is one o
Autor:
A. Caty, Stéphane Culine, Rémi Delva, Agnès Laplanche, Frank Priou, Philippe Beuzeboc, Christine Chevreau, Frederic Rolland, Pierre Kerbrat, Lionnel Geoffrois, Jean-pierre Malhaire, Olivier Rixe, Karim Fizazi, Marie-Stephanie Aubelle
Publikováno v:
European Urology. 65:381-386
Background Whether patients with good prognosis and intermediate/poor prognosis advanced seminoma should be treated differently has not been defined. Objective To assess a risk-adapted chemotherapy regimen in patients with advanced seminoma. Design,
Autor:
Tracy Y. Ansay, Ronald E. Warnick, El Mustapha Bahassi, Christopher M. McPherson, Ahmad Zarzour, Olivier Rixe, Mohamad Adham Salkeni
Publikováno v:
Journal of Neuro-Oncology. 115:27-35
Glioblastoma multiforme (GBM) is the most aggressive brain tumor in adults and remains incurable despite multimodal intensive treatment regimens including surgical resection, radiation and chemotherapy. EGFRvIII is a truncated extracellular mutant of
Autor:
Nicholas N. Vahanian, Frank Mott, Eugene P. Kennedy, Olivier Rixe, Yousef Zakharia, Ramses F. Sadek, David H. Munn, Rimas V. Lukas, Charles J. Link, Howard Colman
BACKGROUND: Indoleamine 2, 3-dioxygenase (IDO) is a key immune-modulatory enzyme within the IDO Pathway that inhibits CD8+ T cells and enhances the suppressor activity of Tregs. IDO is expressed in 50 to 90% of glioblastoma (GBM), and this high expre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bed69032aea0f2a0da129b8ae51c3bb6
https://europepmc.org/articles/PMC4638917/
https://europepmc.org/articles/PMC4638917/
Autor:
Yazdi K. Pithavala, Jean-Philippe Spano, Alejandro D. Ricart, Sinil Kim, Olivier Rixe, Malcolm J. Moore
Publikováno v:
Investigational New Drugs. 30:1531-1539
Purpose Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3, is under investigation for treatment of various solid tumors. The safety and pharmacokinetics of axitinib in co
Publikováno v:
Bulletin du Cancer. 97:S53-S63
New medical strategies have emerged over the past decade for the treatment of advanced renal cell carcinoma based on the discovery of specific molecular abnormalities. However, molecular targeted therapeutics including anti-angiogenics have demonstra
Autor:
Carrie T. Taylor, Erick C. Gamelin, David A. Reardon, John K. Meissen, Andrew B. Lassman, Jason H. Williams, Olivier Rixe, Shilpa Alekar, Timothy F. Cloughesy, Annick Desjardins
Publikováno v:
Neuro-Oncology. 19:vi32-vi32
BACKGROUND PF-06840003 is a highly selective and active IDO1 inhibitor, presumed to cross the blood brain barrier. IDO1, produced by cancer or immune cells, by affecting tryptophan catabolism, producing immunosuppressive metabolites such as kynurenin